Presented by: University of Kentucky Department of Pathology

“The Evolving Molecular Landscape of Thyroid Carcinoma: NTRK Fusions in Diagnosis and Targeted Therapy”

Katie Bussing, MD

Anatomic and Clinical Pathology Resident Physician, PGY-4

University of Kentucky Department of Pathology and Laboratory

          Monday, October 15, 2026

12:00 – 1:00pm

In-Person MS 147 or Zoom: https://us06web.zoom.us/j/88974250308

Passcode: 710932

 Use the QR code to register for this Grand Rounds if you have not already registered.

At the completion of this lecture attendees should be able to:

• Describe the molecular basis and clinicopathologic features of NTRK fusion-positive thyroid carcinoma
• Compare the diagnostic applications and limitations of available methods for NTRK fusion detection
• Explain the role of TRK inhibitors in thyroid cancer management, including treatment efficacy, acquired resistance, and next-generation therapies.

Disclosure of Financial Interest Summary to Learners

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation